Host-Directed Antiviral Research Center, College of Veterinary Medicine, Chonnam National University

- 2010.2 - 2018.3.: Integrated MS/PhD program in Veterinary Medicine, Ph.D in Veterinary Pathology, College of Veterinary Medicine, Chonnam National University, South Korea.

- 2004.3. – 2010.2.: Bachelor in Veterinary Medicine, College of Veterinary Medicine, Chonnam National University, South Korea.

- 2022.9 – present: Assistant Professor, Laboratory of Veterinary Zoonotic Diseases, Chonnam National University, Republic of Korea

- 2022.3-2022.8: Assistant Professor, Korea Zoonosis Research Institute, Jeonbuk National University, South Korea

- 2020.2 – 2022.2: Post-doctoral fellowship, Texas Biomedical Research Institute, TX, USA - 2018.9. – 2020.1: Post-doctoral fellowship, Department of Microbiology and Immunology, University of Rochester Medical Center, NY, USA

1. Piepenbrink MS, Park JG, Deshpande A, Loos A, Ye C, Basu M, Sarkar S, Khalil AM, Chauvin D, Woo J, Lovalenti P, Erdmann NB, Goepfert PA, Truong VL, Bowen RA, Walter MR, Martinez-Sobrido L, Kobie JJ. 2022. Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody. PLoS Pathog. 18 (7): e1010691. Doi: 10.1371/journal.ppat.1010691 (Co-First author)

2. Park JG, Oladunni F, Rohaim M, Dowd JW, Tollitt J, Hodges MDJ, Fathallah N, Assas MB, Alhazmi W, Almilaibary A, Iqbal M, Chang P, Escalona R, Shivanna V, Torrelles J, Worthington J, Jackson-Jones L, Martinez-Sobrido L and Munir M*. 2021. Immunogenicity and Protective Efficacy of an Intranasal Live attenuated Vaccine Against SARS-CoV-2. iScience. doi: https://doi.org/10.1016/j.isci.2021.102941

3. Piepenbrink MS, Park JG, Oladunni FS, Deshpande A, Basu M, Sarkar S, Loos A, Woo J, Lovalenti P, Sloan D, Ye C, Chiem K, Bates CW, Burch RE, Erdmann NB, Goepfert PA, Truong VL, Walter MR, Martinez-Sobrido L, Kobie JJ. 2021. Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters. Cell Rep Med. 16;2(3):100218. doi: 10.1016/j.xcrm.2021.100218 (Co-First author)

4. Oladunni FS, Park JG, Chiem K, Ye C, Pipenbrink M, Walter MR, Kobie J, Martinez-Sobrido L. 2021. Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants. J Virol Methods. 290:114084. doi: 10.1016/j.jviromet.2021.114084 (Co-First author)

5. Oladunni FS, Park JG, Pino-Tamayo P, Gonzale O, Akhter A, Allue-Guardia A, Olmo-Fontánez A, Garcia-Vilanova A, Gautam S, Ye C, Chiem K, Headley C, Dwivedi V, Parodi L, Alfson K, Staples H, Schami A, Garcia J, Whigham A, Neal. Platt II R, Martinez J, Chuba C, Earley S, Rodriguez O, Kavelish K, Escalona R, Hallam C, Christie C, Patterson J, Anderson T, Carrion R, Dick E, Hall-Ursone R, Schlesinger L, Kaushal D, Giavedoni L, Alvarez X, Turner J*, Martinez-Sobrido L* and Torrelles J*. 2020. Lethality of SARS-CoV-2 infection in K18 human angiotensin converting enzyme 2 transgenic mice. Nat. Commun. 11(1):6122. doi: 10.1038/s41467-020-19891-7 (Co-First author)

6. Park JG, Oladunni FS, Chiem K, Ye C, Pipenbrink M, Moran T, Walter, MR, Martinez-Sovrido L. 2020. Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2. J Virol Methods. 287: 113995. doi: https://doi.org/10.1016/j.jviromet.2020.113995

7. Park JG, Ye C, Piepenbrink MS, Nogales A, Wang H, Shuen M, Meyers AJ, Martinez-Sobrido L, Kobie JJ. 2020. A Broad and Potent H1-Specific Human Monoclonal Antibody Produced in Plants Prevents Influenza Virus Infection and Transmission in Guinea Pigs. Viruses. 12(2). doi: 10.3390/v12020167.

8. Park JG, Ávila-Pérez G, Nogales A, Blanco-Lobo P, de la Torre JC, Martínez-Sobrido L. 2020. Identification and characterization of novel compounds with broad spectrum antiviral activity against influenza A and B viruses. J Virol. pii: JVI.02149-19. doi: 10.1128/JVI.02149-19

My research interest has centered on the comprehensive exploration of the life cycle of zoonotic viruses, with a specific emphasis on molecular biology, pathology, and immunology. The primary targets of my investigation include influenza viruses and various coronaviruses, such as the porcine epidemic diarrhea virus (PEDV), feline peritonitis virus (FIPV), Zika virus, and Dengue virus. Since my appointment as an independent investigator in the year 2022, my research endeavors have been primarily directed towards the creation of recombinant viruses and the rigorous assessment of potential antiviral agents and vaccine candidates.